pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

8,127 products tracked

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
Phase 2
efpegerglucagon
efpegerglucagon [INN]
Hyperinsulinemia
Hanmi Pharmaceuticals Co Ltd
0 catalysts
Phase 3
efruxifermin
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
Akero Therapeutics Inc
0 catalysts
Phase 3
efsudenermin alfa
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
EspeRare Foundation
0 catalysts
Phase 3
← prev
page 206 of 271
next →
131
Pain89
Neurology1
eftilagimod alfa
eftilagimod alfa [INN]
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast…
$IMMPIMMUTEP Ltd
0 catalysts
Phase 3
efzimfotase alfa
Hypophosphatasia
Alexion Pharmaceuticals Inc
0 catalysts
Phase 2
efzofitimod
efzofitimod [INN]
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
$ATYRaTYR PHARMA INC
0 catalysts
Phase 2
egalognastat
egalognastat [INN]
Progressive Supranuclear Palsy
Grupo Ferrer Internacional SA
0 catalysts
Marketed
elacestrant hydrochloride
Orserdu (elacestrant hydrochloride)
Metastatic Breast Cancer
Estrogen receptor
A. Menarini Industrie Farmaceutiche Riunite Srl
0 catalysts
Marketed
eladocagene exuparvovec
Kebilidi (eladocagene exuparvovec)
Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency
$PTCPTC INC.
0 catalysts
Marketed
elafibranor
Iqirvo (elafibranor)
Primary Sclerosing Cholangitis
Peroxisome proliferator-activated receptor alphaPeroxisome proliferator-activated receptor delta
Ipsen SA
0 catalysts
Marketed
elagolix sodium + estradiol + norethindrone + elagolix sodium
Oriahnn (elagolix sodium + estradiol + norethindrone + elagolix sodium)
Menorrhagia
$ABBVAbbVie Inc.
0 catalysts
Marketed
elapegademase
Revcovi (elapegademase-lvlr)
Adenosine Deaminase (ADA) Deficiency Related SCID
Leadiant Biosciences Inc
0 catalysts
Marketed
elasomeran
Spikevax (elasomeran [INN])
Coronavirus Disease 2019 (COVID-19)
$MRNAModerna, Inc.
0 catalysts
Phase 3
elebsiran
Hepatitis D
$VIRVir Biotechnology, Inc.
0 catalysts
Phase 3
elebsiran + tobevibart
Hepatitis D
$VIRVir Biotechnology, Inc.
0 catalysts
Phase 2
elecoglipron
Type 2 Diabetes
$AZNASTRAZENECA PLC
0 catalysts
Phase 3
elegrobart
Graves' Ophthalmopathy
Viridian Therapeutics Inc
0 catalysts
Phase 3
elenestinib
Systemic Mastocytosis
Blueprint Medicines Corp
0 catalysts
Preclinical
elesclomol
Endometrial Cancer
Edison Oncology Holding Corp
0 catalysts
Marketed
eletriptan hydrobromide
Eletriptan Hydrobromide (eletriptan hydrobromide)
Migraine
Beximco Pharmaceuticals USA Inc
0 catalysts
Phase 2
elezanumab
Traumatic Spinal Cord Injury
Repulsive guidance molecule A
$ABBVAbbVie Inc.
0 catalysts
Phase 3
elfucose
Inherited Metabolic Disorders
AUG Therapeutics LLC
0 catalysts
Phase 2
elifactant
Neonatal Respiratory Distress Syndrome
Chiesi Farmaceutici SpA
0 catalysts
Marketed
eliglustat tartrate
Eliglustat Tartrate (eliglustat tartrate)
Gaucher Disease Type I
Aizant Drug Research Solutions Pvt Ltd
0 catalysts
Marketed
elinzanetant
Lynkuet (elinzanetant)
Vasomotor Symptoms of Menopause (Hot Flashes)
Bayer USA LLC
0 catalysts
Phase 2
elironrasib
Non-Small Cell Lung Cancer
$RVMDRevolution Medicines, Inc.
0 catalysts
Phase 2
elisrasib
elisrasib [INN]
Solid Tumor
D3 Bio Inc
0 catalysts
Marketed
elivaldogene autotemcel
Skysona (elivaldogene autotemcel [INN])
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Genetix Biotherapeutics Inc
0 catalysts
Marketed
elosulfase alfa
Vimizim (elosulfase alfa)
Mucopolysaccharidosis IV (MPS IV) (Morquio Syndrome )
$BMRNBIOMARIN PHARMACEUTICAL INC
0 catalysts
Marketed
elotuzumab
Empliciti (elotuzumab)
Refractory Multiple Myeloma
Bristol-Myers Squibb Co
0 catalysts